RECENT POSTS
Thursday, March 21, 2019
Tech Data’s Goodwill Adjustment

Tuesday, March 19, 2019
There’s Taxes, and There’s Taxes

Saturday, March 16, 2019
Adventures in Tax Cuts and Net Income

Monday, March 11, 2019
Big Moves in Goodwill, Intangible Value

Friday, March 8, 2019
CVS, Goodwill, and Enterprise Value

Thursday, February 28, 2019
Summary of Our Goodwill Research/ How-To

Wednesday, February 27, 2019
What Does ‘Other’ Mean? An Example

Thursday, February 21, 2019
Another Tale, Buried in the Footnotes

Wednesday, February 13, 2019
Low Latency Calcbench

Monday, February 11, 2019
Now Streaming on Hulu: Red Ink

Thursday, February 7, 2019
Early Look at 2018 Tax Decline

Wednesday, February 6, 2019
You Revised WHAT, Netflix?

Thursday, January 31, 2019
Talking About Huawei Exposure

Wednesday, January 30, 2019
Another Discrepancy in Reported Numbers

Wednesday, January 30, 2019
Finding Revised Facts: Hertz Edition

Wednesday, January 23, 2019
GE Commercial Aviation Services: Bringing Numbers to Light

Monday, January 21, 2019
Differences in Earnings Releases and 10-Ks

Wednesday, January 16, 2019
The Importance of Textual Analysis

Tuesday, January 8, 2019
A Look at Climate Change Disclosures

Wednesday, January 2, 2019
Quants: Point-in-Time Data for Backtesting

Archive  |  Search:
Measuring Big Pharma’s Chemical Dependency
Wednesday, November 28, 2018

Here at Calcbench, high-quality data is what makes us feel hale and healthy. For everyone else, however, today we’re going to take a quick look at sales of blockbuster drugs in the pharmaceutical industry.

We first identified all listed pharmaceutical and life sciences firms in our database. Then we visited our Segments, Rollforwards, and Breakouts page, to find firms that listed specific product sales that exceeded $1 billion in 2017. (That was our threshold for “blockbuster” drugs.) We wanted to know: to what extent do any large pharmaceutical firms depend heavily on blockbuster drugs for their revenue stream?

First place went to Alexion Pharmaceuticals ($ALXN), with 89 percent of its total $3.55 billion in 2017 revenue attributed to one blockbuster drug: Soliris, an intravenous treatment for autoimmune disorders. Alexion reported $3.14 billion in Soliris revenue last year.

Altogether, however, we found 20 pharmaceutical firms dependent on blockbuster drugs. Table 1, below, shows the top 10 as ranked by dependency.



Dependency on blockbuster drugs is useful to know because that hints at broader corporate strategy. A firm can be relatively small, like Alexion, and still depend heavily on a few blockbuster drugs. A firm can also be huge, like Pfizer or Merck, and depend on many blockbuster drugs.

In either case, the same questions arise: what happens when the patents on those blockbusters expire? What is the company doing now to keep the pipeline of future blockbuster drugs full?

Conversely, a firm like Mylan or Abbott might have large total revenues, but no blockbusters. In that case, the firm probably sells generics. There’s nothing wrong with that per se, but it’s a fundamentally different business model with much lower profit margins. So even though Abbott and Gilead Sciences are nearly the same size in total revenue, they are radically different companies because of blockbuster drugs. Abbott has none, Gilead has lots.

A person wouldn’t necessarily know that unless he or she looked at the revenue details for each company. That’s what Calcbench lets you do.

Users would need to export the Segment data into Excel, and then apply a few rules to get the total blockbuster sales by company. But the exercise itself is not hard (took us less than an hour), and then a financial analyst can have that data-drive, specific insight you might want to put in a client note or put to the CFO on that next earnings call.

Calcbench: helping you take the red pill of data analytics since 2011.




FREE Calcbench Premium
Two Week Trial

Research Financial & Accounting Data Like Never Before. More features and try our Excel add-in. Sign up now to try the Premium Suite.